| Primary |
| Acute Lymphocytic Leukaemia |
41.4% |
| Acute Myeloid Leukaemia |
34.3% |
| Acute Promyelocytic Leukaemia |
7.1% |
| Myelodysplastic Syndrome |
5.7% |
| Myocardial Infarction |
5.7% |
| Acute Myelomonocytic Leukaemia |
2.9% |
| Chemotherapy |
2.9% |
|
| Pyrexia |
12.9% |
| Tachycardia |
12.9% |
| Hypotension |
6.5% |
| Septic Shock |
6.5% |
| Toxicity To Various Agents |
6.5% |
| Transient Ischaemic Attack |
6.5% |
| Vomiting |
6.5% |
| Acute Myocardial Infarction |
3.2% |
| Adverse Event |
3.2% |
| Cardiac Failure |
3.2% |
| Device Occlusion |
3.2% |
| Electrocardiogram Qt Prolonged |
3.2% |
| Epilepsy |
3.2% |
| Focal Segmental Glomerulosclerosis |
3.2% |
| Hepatotoxicity |
3.2% |
| Incorrect Dose Administered |
3.2% |
| Inflammation |
3.2% |
| Intracranial Venous Sinus Thrombosis |
3.2% |
| Lung Infection |
3.2% |
| Multi-organ Failure |
3.2% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
37.4% |
| Acute Myeloid Leukaemia |
18.7% |
| Product Used For Unknown Indication |
18.4% |
| B Precursor Type Acute Leukaemia |
3.8% |
| Myelodysplastic Syndrome |
3.8% |
| Lymphocytic Leukaemia |
3.3% |
| Acute Promyelocytic Leukaemia |
2.8% |
| T-cell Type Acute Leukaemia |
1.9% |
| Prophylaxis |
1.5% |
| Precursor B-lymphoblastic Lymphoma |
1.3% |
| Acute Myeloid Leukemia |
1.2% |
| Leukaemia |
1.1% |
| Acute Monocytic Leukaemia |
0.9% |
| B-cell Type Acute Leukaemia |
0.8% |
| Prophylaxis Against Graft Versus Host Disease |
0.6% |
| Bone Marrow Conditioning Regimen |
0.6% |
| Chemotherapy |
0.6% |
| Central Nervous System Lymphoma |
0.5% |
| Immunosuppressant Drug Therapy |
0.5% |
| Myeloid Leukaemia |
0.5% |
|
| Sepsis |
14.4% |
| Thrombocytopenia |
10.6% |
| Off Label Use |
9.3% |
| Platelet Count Increased |
7.2% |
| Tumour Lysis Syndrome |
6.8% |
| Pyrexia |
5.1% |
| White Blood Cell Count Decreased |
4.7% |
| Death |
4.2% |
| Multi-organ Failure |
4.2% |
| Venoocclusive Liver Disease |
4.2% |
| Renal Failure Acute |
3.8% |
| Neutropenia |
3.4% |
| Stomatitis |
3.4% |
| Septic Shock |
3.0% |
| Vomiting |
3.0% |
| Febrile Neutropenia |
2.5% |
| Neutropenic Sepsis |
2.5% |
| Posterior Reversible Encephalopathy Syndrome |
2.5% |
| Renal Failure |
2.5% |
| Staphylococcal Infection |
2.5% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
30.6% |
| Product Used For Unknown Indication |
17.5% |
| Acute Myeloid Leukaemia |
14.9% |
| Chemotherapy |
4.9% |
| Prophylaxis |
4.6% |
| Pyrexia |
4.6% |
| Acute Promyelocytic Leukaemia |
2.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| B Precursor Type Acute Leukaemia |
2.0% |
| Antibiotic Prophylaxis |
1.8% |
| Drug Toxicity Prophylaxis |
1.8% |
| Non-hodgkin's Lymphoma |
1.8% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.8% |
| Drug Use For Unknown Indication |
1.7% |
| Neutropenia |
1.5% |
| Mediastinal Mass |
1.3% |
| Pneumonia |
1.3% |
| Antifungal Prophylaxis |
1.2% |
| Brain Abscess |
1.1% |
| Encephalitis |
1.1% |
|
| Sepsis |
18.8% |
| Vomiting |
8.2% |
| Neurotoxicity |
5.9% |
| Renal Failure |
5.9% |
| Cholestasis |
4.7% |
| Coma |
4.7% |
| Hallucination, Auditory |
4.7% |
| Thrombocytopenia |
4.7% |
| Transaminases Increased |
4.7% |
| Acute Respiratory Distress Syndrome |
3.5% |
| Drug Ineffective |
3.5% |
| Gastrointestinal Haemorrhage |
3.5% |
| Hyponatraemia |
3.5% |
| Oedema Peripheral |
3.5% |
| Pancreatitis Acute |
3.5% |
| Septic Embolus |
3.5% |
| Septic Shock |
3.5% |
| Thrombocytopenic Purpura |
3.5% |
| Toxicity To Various Agents |
3.5% |
| Acute Myeloid Leukaemia |
2.4% |
|
